Point Biopharma’s radiopharmaceutical prostate cancer therapy, PNT2002, reached its main goal in a clinical trial, yet questions were raised about its effectiveness against a similar Novartis drug. The Point therapy showed a 29% reduction in the risk of radiographic progression or death compared to control drugs, but was less effective than expected, potentially impacting the commercial viability of PNT2002. Point and partner Lantheus plan to report further data next year.
Top 10 Certifications for Threat Intelligence: Enhance Your Analytical Abilities
Hey there, Bay Area chums! For those of you interested in a career in cybersecurity, especially in threat intelligence, this article is just for you.